Medartis Holding AG
SIX:MED

Watchlist Manager
Medartis Holding AG Logo
Medartis Holding AG
SIX:MED
Watchlist
Price: 91.1 CHF 2.94% Market Closed
Market Cap: 1.2B CHF

Medartis Holding AG
Investor Relations

Medartis Holding AG operates as a medical device company. The company is headquartered in Basel, Basel-Stadt and currently employs 684 full-time employees. The company went IPO on 2018-03-23. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. The company has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.

Show more
Loading
MED
Swiss Market Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2025
Call Date
Aug 19, 2025
AI Summary
Q2 2025

Strong Organic Growth: Medartis delivered 15.3% organic revenue growth in H1, exceeding expectations and hitting the upper end of guidance.

Guidance Raised: Full-year sales growth guidance increased to 14–16% as momentum continued into July and August.

Tariff Headwind Managed: US tariffs of 39% are expected to have a high single-digit million CHF impact by 2026, but management is mitigating through price increases, US production ramp-up, and cost controls.

Solid Margins Despite FX: Core gross margin held at 81% despite FX and tariff pressure; EBITDA margin slightly improved to 17.8%.

KeriMedical Acquisition Closed: Acquisition completed, with US launch of TOUCH prosthesis set for early 2025 and strong growth expected in Europe and new markets.

US and EMEA Outperformance: The US and EMEA regions both posted growth above 16%, with successful distributor optimization in the US.

Integration on Track: NeoOrtho integration in Brazil progressing smoothly; value and premium strategies remain separate in commercial focus.

Key Financials
Revenue
CHF 123 million
Gross Margin
81%
EBITDA Margin
17.8%
EBIT Margin
8.5%
Cash
CHF 121 million
US Revenue Growth
16.2%
EMEA Revenue Growth
16%
APAC Revenue Growth
14.9%
Earnings Call Recording
Other Earnings Calls
2025
2023

Management

Dr. Thomas Straumann
Founder & Vice Chairman
No Bio Available
Mr. Matthias Schupp
CEO & Member of the Executive Management Board
No Bio Available
Dr. Dirk W. Kirsten Ph.D.
CFO & Member of the Executive Management Board
No Bio Available
Ms. Mareike Loch
VP of EMEA & Member of Executive Management Board
No Bio Available
Mr. Manuel Schaer
CTO & Member of the Executive Board
No Bio Available
Mr. Mario Della Casa
COO & Member of Management Board
No Bio Available
Ms. Inge Maes
Chief Human Resources Officer & Executive Management Board Member
No Bio Available
Ms. Anisha Wharton
Head of Regulatory Affairs
No Bio Available

Contacts

Address
BASEL-STADT
Basel
Hochbergerstrasse 60E
Contacts
+41616333434.0
www.medartis.com